Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade A 41.32 6.41% 2.49
ACAD closed up 6.41 percent on Monday, March 30, 2020, on 83 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical ACAD trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Stochastic Reached Overbought Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.41%
20 DMA Support Bullish 6.41%
Doji - Bearish? Reversal 6.41%
Multiple of Ten Bearish Other 6.41%
Outside Day Range Expansion 6.41%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Chemistry Health Biopharmaceutical Pharmaceutical Industry Chemical Compounds Medication Alzheimer's Disease Parkinson's Disease Schizophrenia Glaucoma Neurological Disorders Chronic Pain Treatment Of Parkinson's Disease Treatment Of Alzheimer's Disease Treatment Of Glaucoma Allergan Muscarinic Agonist

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 53.7
52 Week Low 21.56
Average Volume 1,344,891
200-Day Moving Average 37.61
50-Day Moving Average 40.70
20-Day Moving Average 37.96
10-Day Moving Average 36.65
Average True Range 3.14
ADX 19.4
+DI 21.32
-DI 17.90
Chandelier Exit (Long, 3 ATRs ) 35.72
Chandelier Exit (Short, 3 ATRs ) 39.45
Upper Bollinger Band 45.31
Lower Bollinger Band 30.61
Percent B (%b) 0.73
BandWidth 38.75
MACD Line -0.79
MACD Signal Line -1.53
MACD Histogram 0.743
Fundamentals Value
Market Cap 5.06 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -16.33
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.33
Resistance 3 (R3) 44.91 43.15 44.66
Resistance 2 (R2) 43.15 42.13 43.36 44.43
Resistance 1 (R1) 42.24 41.50 42.70 42.66 44.21
Pivot Point 40.48 40.48 40.71 40.69 40.48
Support 1 (S1) 39.57 39.46 40.03 39.99 38.43
Support 2 (S2) 37.81 38.83 38.02 38.21
Support 3 (S3) 36.90 37.81 37.98
Support 4 (S4) 37.32